Skip to Main Content
Contribute Try STAT+ Today

True to its word, the Trump administration released its 2018 budget that includes a notable change for drug and device makers — they would face a stiff increase in so-called user fees that industry pays for to fund product reviews conducted by the Food and Drug Administration. And the higher fees, which are slated to nearly double to $2.4 billion, would be used to cover the entire cost of those reviews (see page 39).

The notion was widely anticipated after a May 15 letter, which written by US Health and Human Services Secretary Tom Price to the Senate Health, Education, Labor, and Pensions Committee, leaked out. The administration, he wrote, “is seeking to recalibrate how the FDA finances its medical product review work in order to better serve the American people.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.